Home Cart Sign in  
Chemical Structure| 1391426-24-6 Chemical Structure| 1391426-24-6

Structure of Lys05
CAS No.: 1391426-24-6

Chemical Structure| 1391426-24-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lys05 is water soluble salt of Lys01. Lys05 shows potent antitumor activity as a single agent both in vitro and in vivo in multiple human cancer cell lines and xenograft models.

Synonyms: Lys01 trihydrochloride; Lys01; Lys05 (hydrochloride)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lys05

CAS No. :1391426-24-6
Formula : C23H26Cl5N5
M.W : 549.75
SMILES Code : CN(CCNC1=CC=NC2=CC(Cl)=CC=C12)CCNC3=CC=NC4=CC(Cl)=CC=C34.[H]Cl.[H]Cl.[H]Cl
Synonyms :
Lys01 trihydrochloride; Lys01; Lys05 (hydrochloride)
MDL No. :MFCD28963913
InChI Key :JTUYDBHQGOZPQQ-UHFFFAOYSA-N
Pubchem ID :70673566

Safety of Lys05

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Autophagy

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-7 cells 12.3 ± 0.7 µM 24 hours Evaluate antiproliferative activity, results showed BAQ12 and BAQ13 had ~3-fold higher potency than Lys05 Nat Commun. 2020 Sep 15;11(1):4615
HEL cells 5 µM Lys05 reduced HEL cell number independently of ruxolitinib inhibition. Blood Cancer J. 2023 Jul 10;13(1):106
H460 cells 11.1 ± 0.6 µM 24 hours Evaluate antiproliferative activity, results showed BAQ12 and BAQ13 had ~3-fold higher potency than Lys05 Nat Commun. 2020 Sep 15;11(1):4615
HT29 cells 10.6 ± 3.4 µM 24 hours Evaluate antiproliferative activity, results showed BAQ12 and BAQ13 had ~3-fold higher potency than Lys05 Nat Commun. 2020 Sep 15;11(1):4615
BXPC-3 cells 7.8 ± 0.9 µM 24 hours Evaluate antiproliferative activity, results showed BAQ12 and BAQ13 had ~3-fold higher potency than Lys05 Nat Commun. 2020 Sep 15;11(1):4615
PANC-1 cells 13.3 ± 2.0 µM 24 hours Evaluate antiproliferative activity, results showed BAQ12 and BAQ13 had ~3-fold higher potency than Lys05 Nat Commun. 2020 Sep 15;11(1):4615
MIA PaCa-2 cells 16.7± 4.7 µM 24 hours Evaluate antiproliferative activity, results showed BAQ12 and BAQ13 had ~3-fold higher potency than Lys05 Nat Commun. 2020 Sep 15;11(1):4615
A375P cells 0 – 1000 nM 2 weeks To evaluate the effect of Lys05 on long-term clonogenic growth, results showed that Lys05 significantly suppressed long-term clonogenic growth of melanoma cells. Cancer Discov. 2019 Feb;9(2):220-229
A375P cells 3 μM 6 hours To evaluate the effect of Lys05 on lysosomal membrane permeabilization, results showed that Lys05 treatment increased lysosomal membrane permeabilization. Cancer Discov. 2019 Feb;9(2):220-229
MDA-MB-231 cells 20 μM 72 hours Evaluate Lys05's effect on pro-inflammatory cytokine expression; significantly increased Cxcl9, Cxcl10, Ccl5, Ifna, and Ifnb expression Autophagy. 2024 Mar;20(3):525-540
Yumm 2.1 CTNNB1 1, 3, 5, 10μM 16-24 hours To assess the sensitivity of Lys05 in β-catenin-stabilized melanoma cells Cancer Res. 2017 Nov 1;77(21):5873-5885
Yumm 1.7 overexpressing WNT5A 1, 3, 5, 10μM 16-24 hours To assess the sensitivity of Lys05 in Wnt5A-high and β-catenin-low melanoma cells Cancer Res. 2017 Nov 1;77(21):5873-5885
Yumm 1.7 1, 3, 5, 10μM 16-24 hours To assess the sensitivity of Lys05 in Wnt5A-low and β-catenin-high melanoma cells Cancer Res. 2017 Nov 1;77(21):5873-5885
WM164 1, 3, 5, 10μM 16-24 hours To assess the sensitivity of Lys05 in Wnt5A-low and β-catenin-high melanoma cells Cancer Res. 2017 Nov 1;77(21):5873-5885
FS13 1, 3, 5, 10μM 16-24 hours To assess the sensitivity of Lys05 in Wnt5A-high and low β-catenin melanoma cells Cancer Res. 2017 Nov 1;77(21):5873-5885
HL-60 cells 5 µM Lys05 modified neither the response of JAK2 WT HL-60 cells to ruxolitinib. Blood Cancer J. 2023 Jul 10;13(1):106
SET-2 cells 5 µM Lys05 strongly enhanced the cytotoxic effects of ruxolitinib in JAK2V617F cell lines. Blood Cancer J. 2023 Jul 10;13(1):106
K562 cells expressing mRFP-GFP-LC3 10 µM 4 hours To evaluate the inhibitory effect of Lys05 on autophagy flux, results showed that Lys05 treatment led to a significant accumulation of yellow fluorescence, indicating a complete block in autophagy flow. Leukemia. 2019 Apr;33(4):981-994
K562 cells 1 µM and 10 µM 4 hours To evaluate the inhibitory effect of Lys05 on autophagy, results showed that Lys05 at 1 µM and 10 µM concentrations significantly increased the level of membrane-bound LC3B-II, indicating increased accumulation of autophagosomes. Leukemia. 2019 Apr;33(4):981-994
CD34+ CML cells 5 µM To evaluate the inhibitory effect of Lys05 on autophagy, results showed that Lys05 treatment led to accumulation of LC3 puncta and increased levels of autophagy substrates SQSTM1/p62, NBR1, and NCOA4. Leukemia. 2019 Apr;33(4):981-994

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice HT29 colorectal cancer xenograft model Intraperitoneal injection 10 mg/kg Two daily doses To evaluate the effect of Lys05 on tumor growth, results showed that two doses of Lys05 had only a transient effect on tumor growth. Cancer Discov. 2019 Feb;9(2):220-229
Mice Melanoma xenograft models and colon cancer xenograft model Intraperitoneal injection 10 mg/kg to 80 mg/kg Daily dosing or intermittent high-dose administration Lys05 significantly blocks autophagy in vivo and exhibits single-agent antitumor activity. Compared to HCQ, Lys05 more effectively accumulates in and deacidifies lysosomes, leading to sustained autophagy inhibition and tumor growth suppression. High-dose Lys05 causes Paneth cell dysfunction and intestinal toxicity in mice. Autophagy. 2012 Sep;8(9):1383-4
FVB mice Transplanted PyMT-driven mammary tumor model Intraperitoneal injection 50 mg/kg Once daily for one week Assess Lys05's impact on CD8+ T cell infiltration; significantly increased CD8+ T cell infiltration in tumors Autophagy. 2024 Mar;20(3):525-540
Mice Yumm 1.7, Yumm 1.7 overexpressing WNT5A, Yumm 2.1 CTNNB1 melanoma model Intraperitoneal injection 20mg/kg Once daily for 14 days To evaluate the inhibitory effect of Lys05 on melanoma tumor growth with different Wnt status Cancer Res. 2017 Nov 1;77(21):5873-5885
NSG mice HEL cell xenograft model Intraperitoneal injection 32 mg/kg Daily for 14 days Lys05 improved the response to ruxolitinib and significantly prolonged the mice's overall survival. Blood Cancer J. 2023 Jul 10;13(1):106
Nude mice C8161 xenograft Intraperitoneal injection 76 mg/kg Once daily for 48 hours Evaluate the in vivo autophagy inhibition and antitumor efficacy of Lys05. Results showed Lys05 significantly increased AV number and inhibited tumor growth. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8253-8
Wistar rats HCC model Intra-arterial administration 40 mg/kg Single dose Combination therapy coupling autophagy inhibition and TAE in a rat model of HCC resulted in a 21% increase in tumor necrosis compared with TAE alone Radiology. 2017 Jun;283(3):702-710
Mice Scl-tTa-BCR-ABL/GFP-LC3 mouse model 20 mg/kg/day 2 days or 7 days To evaluate the inhibitory effect of Lys05 on autophagy, results showed that Lys05 treatment led to increased GFP-LC3 levels and accumulation of SQSTM1/p62, indicating autophagy inhibition. Additionally, Lys05 treatment reduced the number of LT-HSCs and promoted expansion of MPP and LSK cells. Leukemia. 2019 Apr;33(4):981-994

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.82mL

0.36mL

0.18mL

9.10mL

1.82mL

0.91mL

18.19mL

3.64mL

1.82mL

References

 

Historical Records

Categories